Compare Abeona Therapeutics Inc (ABEO) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $33.26. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| ABEO | TMF | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $7.23 | $44.14 |
52-Week Low | $4.17 | $31.85 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $34.62, down 0.46% on the day, with a bearish technical signal from moving averages. The fund provides 3x daily leveraged exposure to long-term U.S. Treasury bonds, making it highly sensitive to interest rate movements. Recent news highlights significant long-term value erosion, with a $10,000 investment five years ago now worth approximately $1,527, underscoring the risks of daily leverage reset in volatile markets.
The outlook for TMF hinges on the direction of long-term bond yields, with potential for sharp gains if rates fall but severe losses if they rise. It is suited only for short-term, high-risk traders due to leverage decay. Key risks include Federal Reserve policy shifts, inflation trends, and the structural drag of daily rebalancing, making it unsuitable for buy-and-hold investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
